New antibody combo shows promise for Hard-to-Treat cancers

NCT ID NCT06205706

Ongoing Disease control Sponsor: BioInvent International AB Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 27 times

Summary

This early-stage trial tests a new drug called BI-1910, alone or with pembrolizumab, in people with advanced solid tumors (like lung or liver cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see how the body handles the drug. About 35 participants will receive the drug by infusion every 3 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

HM Sanchinarro

Madrid, Spain
Hospital Fundacion Jimenez Diaz

Madrid, Spain
Hospital HM Nou Delfos

Barcelona, 08023, Spain
Hospital universitario Virgen del Rocio

Seville, Spain
Karolinska University Hospital, Solna

Stockholm, Sweden
Lund University Hospital

Lund, Sweden
Rigshospitalet

Copenhagen, Denmark
Universitätsklinikum Essen

Essen, Germany

Conditions

Explore the condition pages connected to this study.

HEPATOCELLULAR CARCINOMA NON SMALL CELL LUNG CANCER SOLID TUMORS SOLID TUMORS